Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thalidomide plus interferon for relapsed or refractory indolent non-Hodgkin lymphoma
ChiCTR-TRC-14004693Phase 4Recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Apr 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of thalidomide in indolent lymphoma (2 arms), sponsored by Henan Cancer Hospital. Primary endpoints: overall response rate, complete remission and 1 more. Started Apr 2014; status: recruiting.
02
Drugs
thalidomide
03
Conditions
indolent lymphoma
Beyond the preview
Go deeper on ChiCTR-TRC-14004693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-14004693.